Detalles de la búsqueda
1.
A Phase II randomized controlled trial evaluated antithrombotic treatment with fesomersen in patients with kidney failure on hemodialysis.
Kidney Int
; 2024 Mar 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-38537676
2.
Pharmacokinetic parameter driven outcomes model predicts a reduction in bleeding events associated with BAY 81-8973 versus antihemophilic factor (recombinant) plasma/albumin-free method in a Chinese healthcare setting.
BMC Med Res Methodol
; 22(1): 215, 2022 08 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35931967
3.
Which Analysis Approach Is Adequate to Leverage Clinical Microdialysis Data? A Quantitative Comparison to Investigate Exposure and Reponse Exemplified by Levofloxacin.
Pharm Res
; 38(3): 381-395, 2021 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-33723793
4.
Relationship between factor VIII activity, bleeds and individual characteristics in severe hemophilia A patients.
Haematologica
; 105(5): 1443-1453, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-31371418
5.
Direct comparison of two extended half-life PEGylated recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A.
Ann Hematol
; 99(11): 2689-2698, 2020 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-32974838
6.
BAY 81-8973 prophylaxis and pharmacokinetics in haemophilia A: Interim results from the TAURUS study.
Eur J Haematol
; 105(2): 164-172, 2020 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-32259334
7.
Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the prevention of venous thromboembolism.
J Thromb Thrombolysis
; 50(1): 12-19, 2020 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-32323190
8.
Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the treatment of venous thromboembolism.
J Thromb Thrombolysis
; 50(1): 1-11, 2020 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-32323191
9.
Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in patients with non-valvular atrial fibrillation.
J Thromb Thrombolysis
; 50(1): 20-29, 2020 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-32323192
10.
Direct comparison of two extended-half-life recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A.
Ann Hematol
; 98(9): 2035-2044, 2019 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-31236667
11.
Population pharmacokinetic (PopPK) modelling indicates that patients switching to BAY 81-8973 from rFVIII-FS can continue their dosing schedule with improved protection.
Haemophilia
; 26(3): e145-e147, 2020 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-32301248
12.
Meta-analysis for diagnostic accuracy studies: a new statistical model using beta-binomial distributions and bivariate copulas.
Stat Med
; 33(1): 17-30, 2014 Jan 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-23873593
13.
Pharmacokinetics, pharmacodynamics, and safety of fesomersen, a novel antisense inhibitor of factor XI, in healthy Chinese, Japanese, and Caucasian volunteers.
Clin Transl Sci
; 17(4): e13784, 2024 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-38563414
14.
Evaluation of covariate effects in item response theory models.
CPT Pharmacometrics Syst Pharmacol
; 13(5): 812-822, 2024 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-38436514
15.
Assessing QTc Effects of Vericiguat Using Two Different Concentration-QTc Modeling Approaches.
Clin Pharmacokinet
; 62(11): 1639-1648, 2023 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37672197
16.
Opportunities and Challenges of Disease Progression Modeling in Drug Development - An IQ Perspective.
Clin Pharmacol Ther
; 114(2): 266-274, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-36802040
17.
Hepatotoxicity of AKR1C3 Inhibitor BAY1128688: Findings from an Early Terminated Phase IIa Trial for the Treatment of Endometriosis.
Drugs R D
; 23(3): 221-237, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37422772
18.
Intra-aortic balloon pump counterpulsation (IABP) for myocardial infarction complicated by cardiogenic shock.
Cochrane Database Syst Rev
; (7): CD007398, 2011 Jul 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-21735410
19.
Optimising prophylaxis in haemophilia A: The ups and downs of treatment.
Blood Rev
; 50: 100852, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34243987
20.
PK/PD modeling of FXI antisense oligonucleotides to bridge the dose-FXI activity relation from healthy volunteers to end-stage renal disease patients.
CPT Pharmacometrics Syst Pharmacol
; 10(8): 890-901, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-34085768